Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 78 5-Year Yield-on-Cost % is 0.00 as of Jul. 28, 2026. GuruFocus rates REVXF with a GF Score™ of 78/100 and a GF Value™ of $41.28 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 323 Medical Devices & Instruments companies, Revenio Group Oyj ranks worse than 309597.21% on this metric.
Revenio Group Oyj's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Revenio Group Oyj's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Revenio Group Oyj's highest Yield on Cost was 8.39. The lowest was 0.63. And the median was 1.93.
REVXF's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.51 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Revenio Group Oyj (OTCPK:REVXF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Revenio Group Oyj 5-Year Yield-on-Cost % Related Terms
REVXF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Revenio Group Oyj's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's 5-Year Yield-on-Cost % falls into.
Revenio Group Oyj 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Revenio Group Oyj (REVXF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Revenio Group Oyj and its competitors. Over the past decade, Revenio Group Oyj's 5-Year Yield-on-Cost % has ranged from 0.63 to 8.39. According to the industry distribution chart, Revenio Group Oyj ranks #999999 out of 323 companies in the Medical Devices & Instruments industry.
Is Revenio Group Oyj's 5-Year Yield-on-Cost % too high?
Revenio Group Oyj's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 8.39. Based on the distribution chart, Revenio Group Oyj ranks #999999 out of 323 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #999999 out of 323 companies for 5-Year Yield-on-Cost %. This places Revenio Group Oyj in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.51. Historically, Revenio Group Oyj's own 5-Year Yield-on-Cost % has ranged from 0.63 to 8.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.51, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.28, compared to a current price of $16.41 — trading 60.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Revenio Group Oyj's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 60.2% below its estimated GF Value™ of $41.28.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $41.28 vs. price of $16.41 (60.2% below fair value)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
78GF Score
Get the complete analysis for REVXF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
